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Abstract 
 
Cyclic nucleotide phosphodiesterases (PDEs) degrade the second messengers cAMP and 
cGMP, thereby regulating multiple aspects of cardiac function. This highly diverse class of 
enzymes encoded by twenty-one genes encompasses eleven families which are not only 
responsible for the termination of cyclic nucleotide signalling, but are also involved in the 
generation of dynamic microdomains of cAMP and cGMP controlling specific cell functions 
in response to various neurohormonal stimuli. In myocardium, the PDE3 and PDE4 families 
are predominant to degrade cAMP and thereby regulate cardiac excitation-contraction 
coupling. PDE3 inhibitors are positive inotropes and vasodilators in human, but their use is 
limited to acute heart failure and intermittent claudication. PDE5 is particularly important to 
degrade cGMP in vascular smooth muscle, and PDE5 inhibitors are used to treat erectile 
dysfunction and pulmonary hypertension. However, these drugs do not seem efficient in heart 
failure with preserved ejection fraction. There is experimental evidence that these PDEs as 
well as other PDE families including PDE1, PDE2 and PDE9 may play important roles in 
cardiac diseases such as hypertrophy and heart failure. After a brief presentation of the cyclic 
nucleotide pathways in cardiac cells and the major characteristics of the PDE superfamily, 
this chapter will present their role in cyclic nucleotide compartmentation and the current use 
of PDE inhibitors in cardiac diseases together with the recent research progresses that could 
lead to a better exploitation of the therapeutic potential of these enzymes in the future. 
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Abbreviations: AC, adenylyl cyclases; AKAP, A-kinase anchoring protein; ANP, atrial 
natriuretic peptide; β-ARs, β-adrenergic receptors; BNP, brain natriuretic peptide; CaM, 
calmodulin; CaMKII, Ca2+/Calmodulin-dependent kinase II; cAMP, cyclic adenosine 
monophosphate; cGMP, cyclic guanosine monophosphate; CN, cyclic nucleotides; CNP, C-
type natriuretic peptide; ECC, excitation-contraction coupling; Epac, exchange protein 
directly activated by cAMP; ERK, extracellular signal-regulated kinase; FRET, Förster 
resonance energy transfer; GAF, cGMP-stimulated phosphodiesterases, Anabaena adenylyl 
cyclases, Fhla transcription factor; GC, guanylyl cyclase; HF, heart failure; ICER, inducible-
cAMP early repressor; IR, ischemia-reperfusion; KO, knockout; LTCC, L-type Ca2+ channels; 
mAKAP, muscle AKAP; NO, nitric oxide; NOS, NO synthase; PDE, cyclic nucleotide 
phosphodiesterase; pGC, particulate guanylyl cyclase; PLB, phospholamban; PKA, cAMP-
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dependent protein kinase; PKG, cGMP-dependent protein kinase; PGE, prostaglandin; PI3Kγ, 
phosphoinositide 3-kinase, γ isoform; RyR2, ryanodine receptor type 2; SERCA, sarco-
endoplasmic reticulum Ca2+-ATPase; sGC, soluble guanylyl cyclase; SR, sarcoplasmic 
reticulum; TnI, troponin I. 
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Introduction 
The cyclic nucleotides (CN) cAMP and cGMP participate in the main regulations of cardiac 
function. They act as second messengers for sympathetic and parasympathetic systems, nitric 
oxide (NO) and natriuretic peptides. CN may exert beneficial or deleterious effects on the 
heart, depending on the strength and duration of the stimulation. Acute elevation of CN 
regulates cardiac excitation-contraction coupling (ECC). However, chronic elevation of 
cAMP contributes to the development of cardiac hypertrophy and progression to heart failure 
(HF), while cGMP possesses anti-hypertrophic properties. The amplitude, duration and 
localization of CN responses are determined by the balance between synthesis of cAMP and 
cGMP by adenylyl and guanylyl cyclases, respectively, and degradation by cyclic nucleotide 
phosphodiesterases (PDEs). PDEs represent the main route to rapidly lower CN levels inside 
the cells, and constitute a highly diverse superfamily of enzymes. Different enzymatic 
properties and localization of multiple PDE isoforms within the cell participate in CN 
compartmentation, which is critical to determine specific physiological responses (Conti et al. 
2014; Steinberg and Brunton 2001). In addition, modification in the expression and activity of 
specific PDEs are observed in several cardiovascular diseases. Thus, the members of the PDE 
superfamily are well placed to be the targets for pharmacological interventions in 
cardiovascular diseases. This is actually the case for a few of them, with PDE inhibitors being 
approved for the treatment of acute heart failure, erectile dysfunction, pulmonary 
hypertension, and intermittent claudication. In the following, we will present an overview of 
the roles of PDEs in cardiac muscle, the current indication of PDE inhibitors in heart diseases 
and the recent research advances holding promises for future therapeutic developments in 
cardiovascular diseases. 
 
CN signaling in cardiac myocytes 
In response to activation of Gs-coupled receptors, cAMP is produced by transmembrane 
adenylyl cyclases, which constitute the main source of cAMP in cardiac cells. Two types of 
guanylyl cyclases (GC) produce cGMP, the soluble GC (sGC) which is activated by NO, and 
particulate GCs (pGC) which constitute the receptors for natriuretic peptides (ANP, BNP and 
CNP). Once synthesized, CN exert their effects by acting through a limited number of cellular 
effectors: for cAMP, these include the cAMP-dependent protein kinase (PKA), cyclic 
nucleotide-gated ion channels (CNG), the exchange proteins directly activated by cAMP 
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(Epac), and the recently discovered popeye-domain containing proteins (Schindler and Brand 
2016). Similarly to cAMP, cGMP may exert its effects through activation of cGMP-
dependent protein kinase (PKG) or CNG channels. Both nucleotides also bind directly to 
PDEs, not only at the catalytic site but also at allosteric sites, thereby modulating their 
activity.  
During the fight or flight response, epinephrine and norepinephrine bind to β-adrenoceptors 
(β-ARs) in cardiomyocytes, leading to cAMP elevation and PKA activation. PKA 
phosphorylation of sarcolemmal L-type Ca2+ channels (LTCC), ryanodine receptors type 2 
(RyR2), phospholamban (PLB, which controls the activity of the Ca2+-ATPase from the 
sarcoplasmic reticulum, SERCA2) and troponin I (TnI) enhances the amplitude and kinetics 
of Ca2+ transients in cardiomyocytes (Figure 1), underlying the classical positive inotropic and 
lusitropic effects of acute sympathetic stimulation. However, sustained stimulation of β-ARs, 
as occurs during hypertension or chronic heart diseases, is detrimental to the heart as it favors 
maladaptive hypertrophic remodeling, apoptosis and arrhythmias. Along with PKA, Epac is 
activated by cAMP and may play an important role in this context. Epac activation triggers a 
signaling pathway involving the phosphatase calcineurin and Ca2+/Calmodulin-dependent 
kinase II (CaMKII) to stimulate hypertrophic growth (Lezoualc'h et al. 2016). CaMKII 
activation, which can also result from PKA-dependent increases in Ca2+, also phosphorylates 
RyR2 and promotes a pro-arrhythmogenic sarcoplasmic reticulum (SR) Ca2+ leak which may 
ultimately lead to chamber dilatation and HF (Ruiz-Hurtado et al. 2012) (Figure 1).  
In the heart, cGMP is often viewed as the mirror of cAMP, opposing its effects on cardiac 
function. Indeed, cGMP can exert negative inotropic effects via PKG-mediated inhibition of 
the L-type Ca2+ current (Méry et al. 1991; Yang et al. 2007) and phosphorylation of TnI to 
decrease myofilament sensitivity to Ca2+ (Layland et al. 2005). In addition, cGMP can 
modulate cAMP levels through regulation of distinct PDEs (see below). One proposed 
mechanism by which cGMP-PKG signaling exerts its antihypertrophic action is by inhibiting 
the calcineurin pathway (Tsai and Kass 2009) (Figure 1). 
  
Overview of the PDE superfamily 
Eleven PDE families that differ in their primary structure, catalytic properties, affinities for 
cAMP and/or cGMP, as well as in their mechanisms of regulation are known in mammals 
(Figure 2). Most PDE families are encoded by several genes, which together generate close to 
100 different PDE isoforms by the use of different translation initiation sites and alternative 
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mRNA splicing. Specific isoforms are designated according to a common nomenclature: PDE 
is followed by a family number (1-11), a capital letter indicating the gene (A, B, C or D) and a 
final number corresponding to the splice variant. Some PDE families selectively hydrolyze 
cAMP (PDE4, 7, 8), while other are specific for cGMP (PDE5, 6, 9). A third category, so 
called dual PDEs, hydrolyzes both cAMP and cGMP (PDE1, 2, 3, 10, 11).  
PDEs share a conserved catalytic domain (C-domain) showing approximately 25–52% AA 
sequence identity, but differ markedly in their regulatory N-domain (Figure 2). N-domains 
contain diverse elements involved in enzyme dimerization, binding of regulatory small 
molecules, phosphorylation and localization. They are characteristic for each family and their 
variants. For instance, the unique distinguishing feature of the PDE1 family is the existence of 
two binding sites for the Ca2+-binding protein calmodulin (CaM) in the N-domain which are 
responsible for enzyme stimulation by Ca2+. Other important domains found in several PDE 
families (PDE2, PDE5, PDE6, PDE10 and PDE11) are the so-called GAF domains (this 
acronym is based on the first letters of the three proteins in which they were first identified: 
G: cGMP-stimulated phosphodiesterases; A: Anabaena adenylyl cyclase; F: Fhla transcription 
factor) which are involved in enzyme dimerization and allosteric regulation by cyclic 
nucleotides. In particular, in PDE2 and PDE5, cGMP-binding to their respective GAF domain 
stimulates enzymatic activity (Martins et al. 1982; Rybalkin et al. 2003). In contrast to PDE2, 
PDE3 is inhibited by cGMP, by direct competition at the catalytic site. The N-domains of 
various PDEs contain phosphorylation sites for distinct kinases which modulate enzymatic 
activity. For instance, long isoforms of PDE4 are phosphorylated by PKA, leading to an 
increase in cAMP-hydrolytic activity (Sette and Conti 1996), whereas PKG phosphorylation 
of PDE5 increases cGMP-hydrolytic activity (Francis et al. 2011). Long isoforms of PDE4D 
have been largely studied in that respect and were shown to be phosphorylated by multiple 
other kinases, including in particular ERK2, ERK5 and CaMKII (Mika et al. 2015). N-
domains are also important for intracellular localization, through specific regions that provide 
membrane association or protein-protein interaction. PDEs can associate with multiple protein 
partners including scaffold proteins such as A-kinase anchoring proteins (AKAPs) or β-
arrestin strategically located within the cells. Recently, an interaction between PDE8 and the 
regulatory subunit RIα of PKA was described which brings together regions spanning the 
phosphodiesterase active site and cAMP-binding sites of RIα to facilitate cAMP hydrolysis 
(Krishnamurthy et al. 2014). More detailed presentations of PDEs including their structure, 
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regulation, physiological roles and pharmacology are available in several recent reviews 
(Conti and Beavo 2007; Francis et al. 2011; Keravis and Lugnier 2012; Maurice et al. 2014).  
 
Role of PDEs in cyclic nucleotide compartmentation 
The notion of compartmentation arose from studies of cAMP signalling in the heart. Almost 
40 years ago, Corbin and co-workers provided evidence that the two subtypes of PKA, 
designated type I and type II, are differentially distributed in the heart: while PKA type I was 
found mostly in the soluble fraction, PKA type II was predominant in the particulate fraction 
(Corbin et al. 1977). It was shown subsequently by Brunton and colleagues that the classical 
positive inotropic effect of β-AR stimulation was accompanied by an increase in cAMP and 
PKA in both fractions, whereas prostaglandin E1 (PGE1) stimulation increased cAMP and 
activated PKA only in the soluble fraction and was devoid of a positive inotropic effect 
(Buxton and Brunton 1983; Hayes et al. 1980). Two main conclusions were drawn from these 
experiments; the first was that cAMP generated by a given receptor does not activate all 
possible PKA molecules in the cell, and the second that active PKA cannot phosphorylate all 
possible substrates (Steinberg and Brunton 2001). The discovery of AKAPs as scaffold 
proteins able to direct PKA to specific subcellular compartments provided a mean to spatially 
restrict PKA activity (Dodge-Kafka et al. 2006; Wong and Scott 2004). A large number of 
PKA type II-specific AKAPs were shown to be associated with critical components of β-AR 
signalling, ECC or hypertrophic signalling in heart (for review see (Diviani et al. 2011)). The 
role of AKAPs in defining the range of PKA action is further supported by recent provocative 
experiments in HEK293 cells suggesting that when PKA is anchored to an AKAP, the 
catalytic subunits of the kinase may not dissociate from the regulatory subunits upon 
hormonal stimulation (Smith et al. 2013). Yet, these sophisticated assemblies of cAMP 
signalling components would not be sufficient to ensure specificity if cAMP can diffuse 
uniformly and indistinctly activate all PKAs present in a given cell. The observation that a 
local β-AR stimulation is much more efficient at stimulating local than remote Ca2+ channels 
in frog cardiomyocytes provided evidence that cAMP diffusion must be hindered. 
Importantly, global PDE inhibition with IBMX increased β-AR stimulation of the remote Ca2+ 
channels, implying that PDEs can act as a diffusion barrier preventing cAMP diffusion 
(Jurevicius and Fischmeister 1996). More direct evidence of the existence of cAMP gradients 
and extended cAMP spreading upon PDE inhibition were subsequently obtained by 
expressing cyclic nucleotide gated channels or Förster resonance energy transfer (FRET) 
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biosensors to measure cAMP in real time in mammalian cardiomyocytes (Leroy et al. 2008; 
Molina et al. 2014; Mongillo et al. 2004; Nikolaev et al. 2006; Nikolaev et al. 2010; Zaccolo 
and Pozzan 2002). Based on experiments performed in HEK293 cells, it was proposed that 
differentially localized PDEs may function as local sinks, that drain cAMP concentration in 
defined domains by locally degrading the second messenger (Terrin et al. 2006). The 
interaction of PDE4D isoforms with several AKAPs facilitating PKA-mediated activation of 
the PDE by PKA also suggest that cAMP can be controlled locally, at the level of one 
macromolecular complex (Dodge et al. 2001; Terrenoire et al. 2009). Additional evidence that 
PDEs control local cAMP signals in cardiomyocytes come from studies showing that the 
contribution of the different PDEs to cAMP degradation depends on the type of Gs-coupled 
receptors generating the signal (Nikolaev et al. 2006; Rochais et al. 2006; Xiang et al. 2005).  
These studies highlighted the predominant role of the PDE4 family in this control, and in 
neonatal cardiac myocytes, distinct PDE4 variants were shown to associate with and regulate 
the cAMP signals generated by β1-ARs versus β2-ARs (Baillie et al. 2003; De Arcangelis et 
al. 2009; Mika et al. 2014; Richter et al. 2008; Richter et al. 2013). The use of cAMP 
biosensors specifically targeted to distinct subcellular compartments also suggests local 
cAMP degradation by distinct PDEs. For instance, targeting of FRET-based cAMP biosensors 
to the plasma membrane and the cytosol indicates a spatially restricted function of a specific 
PDE4 variant (PDE4B) to regulation of subsarcolemmal cAMP generated by β1-ARs in 
neonatal cardiomyocytes (Mika et al. 2014). Moreover, cAMP biosensors targeted to PKA 
type I and II compartments are differentially activated by distinct receptors and PDE 
inhibitors: while cell stimulation with PGE1 or PDE2 inhibition preferentially increase cAMP 
in the PKA type I compartment, stimulation with Iso or PDE4 inhibition preferentially 
increase cAMP in the PKA type II compartment (Di Benedetto et al. 2008). Activation of 
PKA type II correlates with phosphorylation of SR proteins such as PLB by Iso, whereas 
PGE1/E2 fails to phosphorylate PLB (Di Benedetto et al. 2008; Liu et al. 2012). The use of a 
FRET-based PKA biosensor (AKAR) localized to the SR confirmed a lack of PKA activation 
in the SR upon PGE2 stimulation, but also showed that PGE2 is able to blunt β-AR inotropic 
response by activating PDE4D and preventing cAMP generated by β-ARs at the membrane to 
diffuse and activate PKA at the SR (Liu et al. 2012). Inhibition of PDE4 or ablation of the 
PDE4D gene were also shown to enhance PKA activation in the nucleus following a short 
stimulation of β-ARs, suggesting that PDE4D also impedes the diffusion of cAMP from the 
plasma membrane to the nucleus (Haj Slimane et al. 2014).  
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While the works related above argue for a critical role of PDEs in cAMP compartmentation, a 
number of modelling studies suggest that PDEs are not sufficient to establish cAMP gradients 
if cAMP diffusion in the cell cytoplasm is as fast as in water (Feinstein et al. 2012; Iancu et al. 
2007; Rich et al. 2001; Saucerman et al. 2014; Saucerman et al. 2006). Indeed, given their in 
vitro kinetics and estimated concentration in cells, PDEs may not be able to metabolize cAMP 
fast enough to avoid its replacement by diffusion from surrounding areas. Yet, at least for 
PDE2, there is convincing evidence that upon activation of the enzyme by cGMP, hydrolysis 
of cAMP is fast enough to balance the hormonal stimulation of cAMP synthesis (Fischmeister 
and Hartzell 1987; Hartzell and Fischmeister 1986; Nikolaev et al. 2005). Also, it should be 
kept in mind that PDE activity can be enhanced during hormonal stimulation (Conti et al. 
2014). Whereas several studies indicated fast diffusion rates for cAMP in neurons (Bacskai et 
al. 1993; Chen et al. 1999; Nikolaev et al. 2004), recent investigations suggest that cAMP 
diffusion is markedly slower in adult cardiomyocytes (Agarwal et al. 2016; Richards et al. 
2016). The reasons for this are not entirely clear, but the above mentioned recent studies 
propose an important role of the mitochondrial network, acting either as a physical barrier 
(Richards et al. 2016) or as a support for anchored PKA acting as a cAMP buffer system 
(Agarwal et al. 2016). 
 
PDEs and cyclic nucleotide compartmentation in heart failure 
In the 1970s and 1980s, PDE3 inhibitors were discovered to exhibit cardiotonic, inotropic, 
bronchodilatory and vasodilatory activities in several species, and were initially developed as 
cardiotonic agents to replace or add to cardiac glycosides in the treatment of HF (Movsesian 
et al. 2011). However, despite beneficial hemodynamic effects on the short term, chronic use 
of PDE3 inhibitors were associated with increased cardiac arrhythmias and sudden death 
(Packer et al. 1991). Thus, the use of PDE3 inhibitors is now limited to acute decompensated 
HF. Nevertheless, PDE3 inhibitors are targeting several functionally distinct isoforms which 
are co-expressed in the heart, raising the hope that more selective targeting might provide 
some benefits. PDE3 is encoded by two genes, PDE3A and PDE3B. Evidence from global 
PDE3A and PDE3B knockout (KO) mice  indicate that PDE3A but not PDE3B is responsible 
for the inotropic and chronotropic effects of PDE3 inhibitors (Sun et al. 2007). Three isoforms 
of PDE3A are expressed in cardiomyocytes, which differ only in their N-terminal domain, 
giving rise to different intracellular localization (Wechsler et al. 2002). In mice and humans, 
PDE3A1 controls PLB-SERCA2 activity and Ca2+ re-uptake in the SR (Ahmad et al. 2015; 
Beca et al. 2013) (Figure 1). Because dephosphorylated PLB and depressed SERCA2 activity 
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are a hallmark of HF, PDE3 inhibitors targeting specifically the PDE3A1 associated with 
PLB-SERCA2 may improve contractile performance and provide therapy for HF (Movsesian 
2015). However, currently available PDE3 inhibitors have little selectivity for PDE3A versus 
PDE3B isoforms, whose catalytic domains are similar, and no selectivity for individual 
PDE3A isoforms, whose catalytic domains are identical. Phosphorylation of PDE3A1 was 
recently shown to regulate its interaction with SERCA2 (Ahmad et al. 2015). Targeting this 
mechanism may offer an alternative to selectively enhance contractility without the harmful 
effects of global inhibition of PDE3 activity. 
The second major PDE involved in cAMP hydrolysis in the heart is the cAMP-specific PDE4. 
The PDE4 family is encoded by 4 genes (PDE4A-D). Most of our knowledge on the role of 
individual PDE4 subtypes in the heart is limited to PDE4D. Deletion of this gene in mice 
leads to PKA hyperphosphorylation of RyR2, increased sensitivity to exercise-induced 
arrhythmias and a late onset dilated cardiomyopathy (Lehnart et al. 2005). PDE4D isoforms 
are localized in multiple compartments of the cardiomyocyte. For instance, PDE4D3 is 
localized at the perinuclear region, where it is part of a macromolecular complex organized by 
the scaffold protein mAKAP and comprising Epac1 and the kinase ERK5 to regulate 
cardiomyocyte hypertrophy (Dodge-Kafka et al. 2005). This isoform is also present at the 
sarcolemma, where it associates through another AKAP with slowly-activating delayed 
rectifier potassium channels controlling cardiac repolarization (Terrenoire et al. 2009) and at 
myofilaments, in association with another scaffold protein, myomegaline (Verde et al. 2001). 
In addition, as indicated above, distinct PDE4D isoforms were shown to interact with β1-ARs 
and β2-ARs, either directly or indirectly through β-arrestin, and to shape specific 
physiological or pathophysiological responses (Baillie et al. 2003; Berthouze-Duquesnes et al. 
2013; De Arcangelis et al. 2009; Richter et al. 2008; Richter et al. 2013). Finally, similarly to 
PDE3A, PDE4D also associates with the PLB/SERCA2 complex and regulates the SERCA 
pump activity in the mouse heart (Beca et al. 2011) (Figure 1).  
A role for PDE4B in the heart emerged recently when it was identified as an integral 
component of the LTCC complex and the main PDE regulating the LTCC current during β-
AR stimulation (Figure 1). PDE4B KO mice, as PDE4D KO, have an increased susceptibility 
to ventricular arrhythmias during catecholamine stimulation which may be due to enhanced 
Ca2+ influx through LTCC (Leroy et al. 2011). Although RyR2 phosphorylation by PKA did 
not seem to be affected in adult hearts from PDE4B KO mice (Leroy et al. 2011), a recent 
study indicates that it was increased in neonatal myocytes lacking PDE4B (Mika et al. 2014) 
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suggesting that altered RyR2 regulation may also contribute to this arrhythmic phenotype. In 
a recent study in rat ventricular myocytes, we showed that under β-AR stimulation, inhibition 
of PDE4 (as well as inhibition of PDE3) exerted inotropic effects via PKA but led to 
spontaneous diastolic Ca2+ waves via both PKA and CaMKII, suggesting the potential use of 
CaMKII inhibitors as adjuncts to PDE inhibition to limit their pro-arrhythmic effects (Bobin 
et al. 2016). 
As stated above, phosphorylation of certain PDE3 and PDE4 isoforms by PKA activates these 
enzymes, and this constitutes a powerful negative feedback for cAMP signals in 
cardiomyocytes (Leroy et al. 2008; Rochais et al. 2004). This regulation has been shown to be 
facilitated by spatial proximity of PKA and PDEs assembled by the perinuclear mAKAP 
(Dodge-Kafka et al. 2005) or by PI3Kγ, which in addition to its lipid kinase function also acts 
as an AKAP facilitating phosphorylation of PDE3B, PDE4A and PDE4B by PKA (Ghigo et 
al. 2012).  
Although these studies underline the critical role of PDE4 in controlling β-AR stimulation in 
rodents, this family contributes less to the regulation of cardiac contractility in humans, where 
PDE3 predominates (Molenaar et al. 2013). However, in human atrial strips, inhibition of 
PDE3, but also of PDE4 potentiate the arrhythmogenic effect of β-AR stimulation, and PDE4 
activity tends to decrease in the atria of patients with atrial fibrillation (Molina et al. 2012). A 
further understanding of the role of PDE4 in humans may also be important for the pro-
arrhythmic effect of PDE3 inhibitors since PDE3 inhibitors such as milrinone and enoximone 
may also inhibit PDE4 in cardiac preparations (Bethke et al. 1992; Shakur et al. 2002). 
In cardiac hypertrophy and HF, there are profound modifications in the major components of 
the cAMP pathway. These include a decreased density of β1-ARs, an uncoupling of β2-ARs 
from Gs, an increase in Gi and in the G-protein coupled receptor kinase GRK2, and in certain 
models, a decrease in adenylyl cyclase activity (Lohse et al. 2003). In a model of pathological 
hypertrophy induced by pressure overload in rats, we found that the expression and activity of 
PDE3A, PDE4A and PDE4B were decreased, and this was associated with a blunted 
regulation of subsarcolemmal cAMP generated by β-ARs by PDE3 and PDE4 (Abi-Gerges et 
al. 2009). In contrast, in a model of cardiac hypertrophy induced by angiotensin II, an 
increased PDE4 activity was observed, accompanied by an increase in the 69-kDa-PDE4A 
isoform and a decrease in expression of 52- and 76-kDa PDE4D isoforms (Mokni et al. 2010). 
These results suggest that the level of expression of the isoforms of PDE3 and PDE4 is 
specifically regulated by the type of stimulus used to induce cardiac hypertrophy and the stage 
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of the disease. Whereas an increase in cAMP-PDE can participate in desensitization of the β-
AR pathway, a decrease could represent a compensatory mechanism to restore cAMP levels 
and inotropism. However, lower PDE activity also alters the degree of cAMP confinement, 
which could lead to illegitimate or excessive activation of certain pools of PKA or Epac, 
hence promoting maladaptive remodelling and rhythmic disturbances. This is supported by 
the results of a recent study showing that the specific PDE4D5 isoform regulates activation of 
hypertrophic program by Epac1 upon stimulation of β2-AR (Berthouze-Duquesnes et al. 
2013) receptors.  
HF is also accompanied by modifications of the microarchitecture of the myocytes, including 
that of the T-tubular system, manifested as T-tubule loss or as reorganization depending on 
the studies (Louch et al. 2010). These alterations in the T-tubular network not only affect the 
synchrony of Ca2+ release (Heinzel et al. 2002), but are also associated with modifications in 
the distribution of CN signaling components and therefore, CN compartmentation. In a rat 
model of HF, it was shown that β2-ARs redistribute from their normal T-tubular localization 
to the peripheral sarcolemma, leading to diffusive as opposed to constrained cAMP signals 
generated by these receptors (Nikolaev et al. 2010). In a more recent study, the local 
regulation of cAMP by PDEs in the vicinity of SERCA2 was compared in transgenic mice 
with cardiac-specific expression of a PLB-targeted cAMP biosensor, and modifications 
induced by transverse aortic constriction were analysed (Sprenger et al. 2015). In agreement 
with their known localization within the SERCA2 complex (Beca et al. 2013; Beca et al. 
2011), both PDE3 and PDE4 were found to regulate cAMP in this microdomain. 
Interestingly, during hypertrophy and early HF, there was a specific rearrangement of the 
PDEs regulating this specific cAMP pool, with a decreased contribution of PDE4 and an 
increased contribution of PDE2 (Sprenger et al. 2015). These results indicate that PDE 
alterations in cardiac disease include redistribution of PDE variants in discrete 
microcompartments of cardiomyocytes, as shown for PDE2 ans PDE3 at the membrane 
(Perera et al. 2015). 
The dual specific PDE2 represents a minor part of cAMP-hydrolytic activity in the normal 
heart, but the cAMP-hydrolytic activity of this PDE is stimulated 5 to 30-fold by cGMP, and 
this was shown to inhibit cardiac LTCC in various species including humans (Fischmeister et 
al. 2005). Subsequently, measurements with FRET-based sensors in neonatal rat 
cardiomyocytes showed that by decreasing the level of cAMP, PDE2 counteracts the effects 
of a β-AR stimulation downstream of β3-ARs (Mongillo et al. 2005). In contrast to PDE3 and 
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PDE4, which expression and activity are generally decreased in pathological hypertrophy and 
HF (Abi-Gerges et al. 2009; Ding et al. 2005; Osadchii 2007), we found recently that PDE2 is 
increased in animal models as well as in human HF (Mehel et al. 2013). PDE2 inhibition 
partially restores β-AR responsiveness in diseased cardiomyocytes, suggesting that PDE2 
enhancement in HF constitutes a protective mechanism against excessive β-AR stimulation. 
This hypothesis was confirmed in a more recent study using a transgenic mouse model with a 
cardiac-specific overexpression of PDE2 (Vettel et al. 2016). Transgenic increase in PDE2 
abundance in mice lowers heart rate, but preserves cardiac output due to greater cardiac force. 
Increased PDE2 abundance was found to be cardioprotective in vivo in acute 
catecholaminergic stress and after myocardial infarction without compromising contractile 
performance (Vettel et al. 2016). However, according to another recent study, PDE2 could 
exert a pro-hypertrophic effect by blunting PKA-mediated phosphorylation of NFAT 
(Zoccarato et al. 2015). Further studies are needed to fully understand the role of PDE2 in HF 
(Wagner et al. 2016; Zoccarato et al. 2016). 
Similarly to PDE2, PDE1 and PDE5 were reported to be upregulated in pathological 
hypertrophy and HF (Miller et al. 2009; Pokreisz et al. 2009; Vandeput et al. 2007). Because 
PDE1 and PDE5 preferentially (PDE1A) or specifically (PDE5) degrade cGMP, their increase 
in HF can clearly be seen as maladaptive. Accordingly, transgenic mice with cardiac-specific 
overexpression of PDE5 are predisposed to adverse remodelling after myocardial infarction 
(Pokreisz et al. 2009), whereas on the contrary, pharmacological inhibition of PDE1 (Miller et 
al. 2009) or PDE5 (Takimoto et al. 2005) reduces hypertrophy and improves cardiac pressure 
and volume overload. Numerous animal studies have shown that PDE5 inhibitors protect 
against ischemia/reperfusion (I/R) injury, doxorubicin cardiotoxicity, ischemic and diabetic 
cardiomyopathy, and Duchenne muscular dystrophy (Das et al. 2015). However, it remains 
controversial whether significant levels of PDE5 are expressed in the myocardium, raising the 
possibility that the beneficial effects of PDE5 inhibitors involve other mechanisms including 
inhibition of PDE1 (Degen et al. 2015; Lukowski et al. 2014). In patients with systolic HF, 
sildenafil decreased pulmonary vascular pressure and increased peak oxygen consumption 
and cardiac index (Lewis et al. 2007). Sildenafil also improved left ventricular diastolic 
function, cardiac geometry, and clinical status in patients with systolic HF (Guazzi et al. 
2011) and improved diabetic cardiomyopathy (Giannetta et al. 2012). However, despite 
encouraging results in an initial mono-center study (Guazzi et al. 2011), chronic therapy with 
sildenafil was not associated with clinical benefit in patients with diastolic HF in a larger, 
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multi-center study (Redfield et al. 2013). Ongoing trials with PDE5 inhibitors include testing 
for the gender response to tadalafil in left ventricular hypertrophy associated to diabetic 
cardiomyopathy (NCT01803828).  
Two other PDEs were recently proposed to participate in cGMP degradation in the heart. 
Experiments performed in isolated cardiomyocytes from transgenic mice expressing a FRET-
based cGMP biosensor have suggested that PDE3, which is classically known to degrade 
preferentially cAMP, may also be involved in the control of cGMP levels (Gotz et al. 2014). 
In addition, the cGMP-specific PDE9 was found to be expressed in rodent and human heart 
and to be up-regulated in hypertrophy and HF (Lee et al. 2015). PDE9 genetic ablation or 
pharmacological inhibition appears to protect the heart against pathological remodeling 
during pressure-overload. Moreover, PDE9 inhibition reverses pre-established heart disease in 
a NO synthase (NOS) activity independent manner, whereas PDE5 inhibition requires active 
NOS, which is decreased in HF. This is because PDE9 seems to hydrolyze specifically cGMP 
generated by natriuretic peptides, whereas PDE5 controls cGMP generated by NO (Castro et 
al. 2006; Takimoto et al. 2007). We had shown previously that PDE2 is critical to regulate 
subsarcolemmal cGMP levels in response to pGC activation in adult cardiomyocytes (Castro 
et al. 2006), thus raising the question of whether PDE2 and PDE9 exert a redundant or distinct 
regulation of natriuretic peptide signaling. 
 
PDEs as therapeutic targets in ischemia reperfusion injury? 
Manipulation of PDE activity may also prove protective in the context of ischemia-
reperfusion (IR) injury. Indeed, PDE5 inhibitors were shown to reduce infarct size in rabbits 
and mice. They also decreased cell death in isolated cardiomyocytes, suggesting that part of 
this effect is independent of vasodilation. Several mechanisms appear to be involved in these 
effects, including increased NO synthase expression, cGMP elevation, PKG activation and 
opening of mitochondrial KATP and Ca
2+-activated K+ channels (Das et al. 2015). PDE3 
inhibitors have also been reported to reduce infarct size when applied before sustained 
ischemia, thus mimicking the cardioprotection conferred by ischemic preconditioning 
(Fukasawa et al. 2008; Sanada et al. 2001; Tosaka et al. 2007). A recent study using KO mice 
for either PDE3A or PDE3B strongly suggests that PDE3B is the isoform mediating the 
cardioprotective effect of PDE3 inhibitors in this context. Indeed, PDE3B KO mice, but not 
PDE3A KO mice, were protected against ischemia-reperfusion injury. This protective effect 
appears to involve cAMP/PKA mediated opening of mitochondrial Ca2+-activated K+ 
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channels and assembly of ischemia-induced caveolin 3 enriched fractions (Chung et al. 2015). 
Somehow at odds with the above mentioned cardioprotective effect of PDE3 inhibitors, mice 
with cardiac-specific overexpression of PDE3A1 were protected during ischemia-reperfusion 
injury (Oikawa et al. 2013). In addition to regulating SERCA2, PDE3A1 also acts as a 
negative regulator of cardiomyocyte apoptosis, by controlling the expression of the 
transcriptional repressor and pro-apoptotic factor, ICER (inducible- cAMP early repressor) 
(Yan et al. 2007). Inhibition of this mechanism in mice with cardiac-specific overexpression 
of PDE3A1 was associated with protection during ischemia-reperfusion (Oikawa et al. 2013). 
Collectively, these studies suggest that PDE3A and PDE3B may play an opposite role during 
ischemia-reperfusion, which may be linked to their differential localization and the control of 
discrete cAMP pools in cardiomyocytes (Chung et al. 2015).  
 
Concluding remarks 
Soon after the discovery of cAMP and cGMP by Sutherland and colleagues more than 50 
years ago, an enzymatic activity that could degrade these second messengers was described 
(Sutherland and Rall 1958). Since then, the large diversity and complexity of the PDE 
superfamily has been unveiled, and the critical role of these enzymes in the cardiovascular 
system demonstrated. After several disappointments in the development of PDE3 and PDE4 
inhibitors due to their adverse effects (mortality and emesis, respectively), the success in 
PDE5 inhibitors to treat erectile dysfunction associated with an increasing understanding of 
PDE biology has raised new hopes that manipulating PDE activity with greater specificity is 
possible and should yield therapeutic benefits. However, the targeting of individual PDE 
isoforms located in distinct subcellular compartments to regulate local cAMP and/or cGMP 
concentrations and a specific cell function is challenging. Knowledge of the protein partners 
and of the molecular mechanisms that govern this specific localization allows to envisage the 
displacement of specific PDE pools by small molecules or peptides that disrupt protein-
protein interaction, with potentially fewer adverse effects than global inhibition of an entire 
PDE family. Recent examples of such strategy include the disruption of PDE4 from heat 
shock protein 20 (HSP20) in cardiomyocytes, resulting in hyper-phosphorylation of HSP20 
and attenuated cardiac hypertrophic growth (Martin et al. 2014; Sin et al. 2011) and the 
disruption of Epac1-PDE3B and Epac1-PDE4D complexes involved in the control of 
endothelial cell adhesion, spreading and permeability (Rampersad et al. 2010; Wilson et al. 
2011). Another interesting strategy is the development of allosteric inhibitors of PDEs, for 
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instance targeting the GAF domain of PDE5 to block enzyme activation but not its basal 
activity (Schultz et al. 2011) or exploiting sequence differences outside the active site to reach 
isoform selectivity in the case of PDE4B and PDE4D (Burgin et al. 2010; Fox et al. 2014).  
The allosteric mode of regulation could also allow the discovery of small molecules acting as 
activators of specific PDEs, which may actually be useful in correcting the detrimental effects 
of excessive β-AR stimulation observed in HF.  
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Figure legends 
 
 
Figure 1: Cyclic nucleotides metabolism in cardiac myocytes.  
The major PDEs expressed in cardiac myocytes are indicated together with their subcellular 
localization in relation to their role in regulating hypertrophic growth and excitation-
contraction coupling. For simplicity, the PDE family and – when relevant – the gene are 
indicated but not the specific splice variants. AC, adenylyl cyclase; AKAP, A-kinase 
anchoring protein; CaMKII, Ca2+-Calmodulin kinase II; CaN, calcineurin; GPCR, G-protein 
coupled receptor; pGC, particulate guanylyl cyclase; sGC, soluble guanylyl cyclase. 
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Figure 2: The eleven mammalian PDE families. The conserved catalytic domain (shown in 
red) is located in the carboxy-terminal portion of the PDEs. The catalytic domain of PDE3 
contains a unique 44-amino-acid insert (shown in black). Many of the PDE families contain 
amino-terminal subdomains (such as GAF domains, transmembrane domains, targeting 
domains, upstream conserved regions (UCRs), PAS domains and REC domains) and N-
terminal hydrophobic regions that are important in subcellular localization, in the 
incorporation of PDEs into compartmentalized signalosomes, in interactions with signalling 
molecules and molecular scaffolds, and in the regulation of PDE activity. GAF domains 
regulate the allosteric binding of cGMP (to PDE2, PDE5, PDE6 and PDE11), the allosteric 
binding of cAMP (to PDE10) and the regulation of catalytic activity (in PDE2, PDE5 and 
PDE6). (Modified from ref.(Maurice et al. 2014)) 
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